Crizotinib Intermediate CAS 877399-00-3 Purity ≥98.0% (HPLC) e.e ≥99.0%
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of (R)-5-Bromo-3-[1-(2,6-Dichloro-3-Fluorophenyl)ethoxy]pyridin-2-Amine (CAS: 877399-00-3) with high quality, intermediate of Crizotinib (CAS: 877399-52-5). Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase Crizotinib Intermediate, Please contact: alvin@ruifuchem.com
| Chemical Name | (R)-5-Bromo-3-[1-(2,6-Dichloro-3-Fluorophenyl)ethoxy]pyridin-2-Amine |
| Synonyms | Crizotinib Intermediate; Crizotinib Bromide Impurity; 5-Bromo-3-[(1R)-1-(2,6-Dichloro-3-Fluorophenyl)ethoxy]-2-Pyridinamine; [5-Bromo-3-[(1R)-(2,6-Dichloro-3-Fluorophenyl)ethoxy]pyridin-2-yl]amine |
| Stock Status | In Stock, Commercial Production |
| CAS Number | 877399-00-3 |
| Molecular Formula | C13H10BrCl2FN2O |
| Molecular Weight | 380.04 g/mol |
| Melting Point | 108.0 to 113.0℃ |
| Density | 1.643 |
| COA & MSDS | Available |
| Sample | Available |
| Origin | Shanghai, China |
| Category | Intermediate of Crizotinib (CAS: 877399-52-5) |
| Brand | Ruifu Chemical |
| Items | Inspection Standards | Results |
| Appearance | Light Yellow To Yellow Powder to Crystal | Complies |
| Melting Point | 108.0 to 113.0℃ | Complies |
| Purity (HPLC Area) | ≥98.0% | 99.1% |
| Enantiomeric Excess (E.E) | ≥99.0% | 99.5% |
| Infrared Spectrum | Conforms to Structure | Complies |
| 1 H NMR Spectrum | Conforms to Structure | Complies |
| Conclusion | This product has been tested & complies with the specifications | |
| Shelf Life | 2 Years if Stored Properly | |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry (2~8℃) and well-ventilated warehouse away from incompatible substances. Protect from light and moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
(R)-5-Bromo-3-[1-(2,6-Dichloro-3-Fluorophenyl)ethoxy]pyridin-2-Amine (CAS: 877399-00-3) is used as an intermediate of Crizotinib (CAS: 877399-52-5).
Crizotinib is definitely an anti-cancer drug becoming an alk (anaplastic lymphoma kinase) and ros1 (c-ros oncogene 1) inhibitor, approved for treatment of some non-small cell lung carcinoma (NSCLC) in the usa and some other countries, and undergoing numerous studies testing its safety and efficacy in anaplastic large cell lymphoma, neuroblastoma, and other advanced solid tumors in adults and children.
Crizotinib is a targeted therapy drug for non-small cell lung cancer developed by Pfizer, USA, secorri is a frontier and epoch-making drug in the field of targeted therapy for lung cancer. It was approved for marketing in the United States in August 2011 and was written into international lung cancer treatment guidelines at the end of the year as a first-line drug for ALK-positive patients. Co-approved with Crizotinib is the first genetic diagnosis method using fluorescence in situ hybridization (FISH)-VSIs ALK Break Apart FISH Probe Kit, this is the method currently used in global clinical trials to detect EML4-ALK fusion genes in NSCLC. This test will help identify patients who may benefit from Crizotinib treatment.
Crizotinib is a selective tyrosine kinase receptor inhibitor used in the therapy of selected cases of advanced non-small cell lung cancer. It is a dual ATP competitive inhibitor of tyrosine kinases c-MET (Mesenchymal-Epithelial Transition Factor) kinase (cellular IC50=8 nM) and ALK (cellular IC50=20 nM), both of which are important targets for cancer chemotherapy. When Crizotinib was tested for selectivity versus other kinases it was found to have enzyme IC50's within 100-fold multiples of c-MET for 13 of the 120 kinases tested. In cellular assays, Crizotinib was found to inhibit RON (recepteur d’origine nantais) kinase with a 10-fold selectivity window over c-MET. Altogether, this agent inhibits tumor cell growth. XALKORI®(Crizotinib) is a prescription medicine used to treat people with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in either a gene called ALK (anaplastic lymphoma kinase) or a gene called ROS1. It is not known if XALKORI is safe and effective in children.
